News >

T-DM1 Approved for HER2-Positive Metastatic Breast Cancer

Ben Leach
Published: Friday, Feb 22, 2013

Dr. Richard Pazdur

Richard Pazdur, MD

The FDA has approved ado-trastuzumab emtansine (Kadcyla), also known as T-DM1, for HER2-positive metastatic breast cancer.

Verma S, Miles D, Gianni L. Updated overall survival results from EMILIA, a phase 3 study of T-DM1 (T-DM1) vs capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC). Paper presented at: 37th European Society for Medical Oncology Congress; September 28-October 2, 2012; Vienna, Austria. Abstract LBA12.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances In™ Tumor Testing: Interpreting Genomic Profiles to Optimize Breast Cancer TreatmentJun 29, 20191.5
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x